Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Louisiana Bevacizumab Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield of LouisianaPolicy MA-214

    Bevacizumab Products - Oncology

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy MA-214 alerts

    Get alerted when Policy MA-214 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This Medicare Advantage medical policy governs coverage and prior authorization for bevacizumab reference and biosimilar products used for oncology indications. Coverage depends on contract benefits, medical necessity, and, for non-preferred products, failure or expected ineffectiveness or adverse reaction to both preferred biosimilars unless an exception applies.

    Policy Summary
    PayerBlue Cross Blue Shield of Louisiana
    PolicyBevacizumab Products - Oncology
    Policy CodePolicy MA-214
    Change TypeModified
    Effective DateJan 1, 202743d
    Last ReviewOct 20, 2026
    Next Review DateOct 1, 2027
    Key ActionObtain prior authorization for all codes listed in this Medical Policy.
    SourceLink
    POLICY UPDATE CHANGES

    The preferred bevacizumab biosimilar was changed from Mvasi to Vegzelma.

    The policy title and patient-selection note were revised to specify that the policy applies to oncology indications and not intravitreal use.

    A Novitas Medicare Billing Article link was added for intravitreal bevacizumab use.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2Preferred biosimilars
    5Non-preferred products subject to the selection criterion
    7Bevacizumab products discussed
    AllCodes requiring prior authorization
    90 daysTransition period for ongoing authorized treatment

    Coverage Criteria

    Preferred Products

    Eligible coverage requires all of the following:

    Coverage requirements

    • Benefits are available in the member's contract or certificate, and medical necessity criteria and guidelines are met.

    Non-preferred Oncology Products

    Coverage may be eligible when all of the following are met:

    Non-preferred oncology product coverage

    • Benefits are available in the member's contract or certificate, and medical necessity criteria and guidelines are met.
    • Patient-selection requirement

      • The patient has tried and failed both bevacizumab-adcd (Vegzelma) and bevacizumab-bvzr (Zirabev), such as because of intolerance or inadequate response.Both preferred biosimilars
      • Clinical evidence or patient history indicates that Vegzelma or Zirabev will be ineffective or cause an adverse reaction to the patient.

    Medical Necessity

    The service must meet the Health Plan's medical necessity definition.

    Medical necessity

    • The service is appropriate for the diagnosis or treatment of the patient's illness, injury, or disease; is not primarily for the personal comfort or convenience of the patient, physician, or other health care provider; and is not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results.

    Medicare Advantage Coverage Framework

    For Medicare Advantage members, apply applicable Medicare coverage guidelines first.

    Medicare Advantage coverage framework

    • Review applicable Medicare statutes, regulations, National Coverage Determinations, and Local Coverage Determinations.
    • When coverage criteria are not fully established in applicable Medicare statutes, regulations, National Coverage Determinations, or Local Coverage Determinations, internal coverage criteria may be applied as a summary of the evidence, resources, and rationale supporting the criteria.

      Use the Medicare Coverage Database to determine whether an NCD or LCD addresses the service.

    The patient-selection criterion applies to oncology indications only. It does not apply to intravitreal use; providers should refer to the referenced Novitas Medicare Billing Article for intravitreal bevacizumab.

    Investigational or experimental services are not covered, including drugs, devices, procedures, or services provided under the investigational arm of a clinical trial or study, unless an applicable Centers for Medicare and Medicaid Services exception applies.

    Federal and state law and the applicable health insurance contract take precedence over this Medical Policy. Contract definitions and specific contract provisions or exclusions must be considered first when determining coverage eligibility.

    For oncology use, bevacizumab (Avastin), Alymsys, Avzivi, Jobevne, and Mvasi are considered not medically necessary when the patient-selection criterion is not met. The criterion generally requires prior trial and failure of both preferred biosimilars, Vegzelma and Zirabev, unless the applicable exception is supported by clinical evidence or patient history.

    Coding Information

    CPT/HCPCS codesHCPCS
    J3490Code listed under codes used to identify services associated with this policy
    J3590Code listed under codes used to identify services associated with this policy
    J9035Code listed under codes used to identify services associated with this policy
    Q5126Code listed under codes used to identify services associated with this policy
    Q5160Code listed under codes used to identify services associated with this policy
    Deleted codeHCPCS
    Q5129Delete code effective 01/01/2027
    ICD-10 Diagnosis: All related diagnosesICD-10
    No codes listed

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    All codes listed in Medical Policy MA-214 require prior authorization before services are provided.

    • Applies to all Medical Policy codes.
    Prior Authorization

    Utilization and Clinical-Criteria Review

    Prior authorization supports appropriate utilization and alignment with current clinical guidelines. Submit requests for review before treatment is initiated.

    • Authorization is required even when the requested service appears clinically appropriate.
    Step Therapy

    Preferred Biosimilar Trial Required

    Clinical Background

    Bevacizumab products are used for a variety of FDA-approved oncologic conditions and may also be used for off-label, guideline-driven oncologic indications. Avastin is the FDA-approved reference product; Mvasi, Zirabev, Alymsys, Avzivi, Jobevne, and Vegzelma are biosimilars with no clinically meaningful differences from Avastin. For oncology coverage, the policy establishes a preferred-biosimilar sequence using Vegzelma and Zirabev.

    Policy Definitions

    Biosimilar
    DefinitionA biological product that is highly similar to an existing FDA-approved reference product.
    Clinical differencesThe product has no clinically meaningful differences from the reference product.
    Policy exampleAvastin is the FDA-approved reference product for the bevacizumab products addressed by this policy.
    Medically Necessary
    DefinitionHealth care services, treatment, procedures, equipment, drugs, devices, items, or supplies that a provider exercising prudent clinical judgment would provide to prevent, evaluate, diagnose, or treat an illness, injury, disease, or its symptoms.
    Practice standardThe service follows nationally accepted standards of medical practice.

    Initial Therapy With a Non-Preferred Product

    Initial Therapy with Non-preferred Product

    For initial use of a non-preferred bevacizumab product in oncology, one of the following patient-selection pathways must be met:

    Preferred-product failure or exception

    • The patient has tried and failed both Vegzelma and Zirabev, such as because of intolerance or inadequate response.Both preferred biosimilars
    • Clinical evidence or patient history indicates that Vegzelma and Zirabev will be ineffective or cause an adverse reaction to the patient.

    Preferred Biosimilar Sequence

    StepRequirementProducts subject to step therapy
    1Try and fail both preferred biosimilars—Vegzelma and Zirabev—such as because of intolerance or inadequate response. An exception may apply when clinical evidence or patient history indicates that either product would be ineffective or cause an adverse reaction.Avastin, Alymsys, Avzivi, Jobevne, or Mvasi for oncology indications

    Product and Reference-Product Information

    Step Therapy

    Try Vegzelma before non-preferred Avastin use

    Bevacizumab (Avastin) is subject to the preferred-product relationship for oncology coverage. Patients generally must try and fail Vegzelma before use of a non-preferred product.

    • Vegzelma is a preferred bevacizumab biosimilar.
    Step Therapy

    Try Zirabev before non-preferred Avastin use

    Bevacizumab (Avastin) is subject to the preferred-product relationship for oncology coverage. Patients generally must try and fail Zirabev before use of a non-preferred product.

    • Zirabev is a preferred bevacizumab biosimilar.
    Policy Summary
    PayerBlue Cross Blue Shield of Louisiana
    PolicyBevacizumab Products - Oncology
    Policy CodePolicy MA-214
    Change TypeModified
    Effective DateJan 1, 202743d
    Last ReviewOct 20, 2026
    Next Review DateOct 1, 2027
    Key ActionObtain prior authorization for all codes listed in this Medical Policy.
    SourceLink
    On This Page
    Coverage CriteriaCoding InformationAuthorization and Documentation RequirementsClinical BackgroundPolicy DefinitionsInitial Therapy With a Non-Preferred ProductPreferred Biosimilar SequenceProduct and Reference-Product Information

    For oncology use of the listed bevacizumab products, document that the patient has tried and failed both preferred biosimilars before requesting coverage of a non-preferred product.

    • Preferred biosimilars: bevacizumab-adcd (Vegzelma) and bevacizumab-bvzr (Zirabev).
    • The requirement applies to oncology indications only; it does not apply to intravitreal use.

    Unsupported block type: documentationТ

    Documentation Required

    Transition Authorization Documentation

    For an ongoing course of treatment previously authorized by another health plan, submit documentation of the prior authorization from the previous plan.

    • The service must be the same service under the same type of in-network benefit.
    • The course of treatment must otherwise be covered under the Blue Advantage health plan.
    Documentation Required

    Documentation for 90-Day Transition Requests

    When requesting transition coverage, provide the prior plan's authorization documentation to Blue Advantage within the applicable transition period.

    • A 90-day transition period may apply when a member changes health plans during an ongoing authorized course of treatment.
    • Documentation may be submitted by the member or provider.
    Denial Risk

    Failure to Meet Biosimilar Step Criterion

    Use of the listed bevacizumab products for oncology indications may be considered not medically necessary when the patient-selection criterion is not met.

    • The criterion requires trial and failure of both preferred biosimilars unless an applicable clinical exception is documented.
    Denial Risk

    Investigational or Experimental Use Excluded

    Investigational or experimental services are not covered, including drugs, devices, procedures, or services provided under the investigational arm of a clinical trial or study, unless coverage is mandated by CMS.

    • Coverage is limited to routine services for Category A IDE studies and devices and related services for Category B IDE studies when not supplied by the trial sponsor.
    Denial Risk

    Medical Necessity and Cost-Effectiveness

    Coverage may be denied when the service is primarily for personal comfort or convenience, is more costly than an alternative service or sequence of services expected to produce equivalent results, or does not meet medical-necessity requirements.

    • Medical-necessity determinations consider nationally accepted standards of medical practice and credible scientific evidence.
    Documentation Required

    Transition Authorization Conditions

    Blue Advantage may honor a previous health plan's authorization for the same ongoing course of treatment for a 90-day transition period, but the authorization is not automatic.

    • Required documentation from the previous health plan must be provided by the member or provider.
    • The service must be covered under the Blue Advantage plan and provided under the same type of in-network benefit.
    • Failure to provide documentation or submit it within the transition period may prevent the prior authorization from being honored.
    Clinical appropriatenessThe service is clinically appropriate in type, frequency, extent, level of care, site, and duration, and is considered effective for the patient's illness, injury, or disease.
    Convenience and costThe service is not primarily for personal comfort or convenience and is not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results.
    Biosimilar
    DefinitionA biological product that has no clinically meaningful differences from an existing FDA-approved reference product.
    FDA approvalFDA-approved biosimilars meet the FDA's rigorous standards for approval for the indications described in the product labeling.
    Safety and effectivenessOnce approved by the FDA, the biosimilar's safety and effectiveness have been established, as they have been for the reference product.
    Nationally Accepted Standards of Medical Practice
    Evidence baseStandards based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community.
    Specialty recommendationsStandards include recommendations from relevant physician specialty societies.
    Clinical expertiseStandards include the views of physicians practicing in relevant clinical areas.
    Additional considerationsOther relevant factors may also be considered.
    Billing Rule

    Reference-product substitution is not step therapy

    Coverage of an FDA-approved biosimilar as an alternative to its reference product is not considered a form of step therapy by the Health Plan.

    • FDA-approved biosimilars have no clinically meaningful differences from the FDA-approved reference product.
    • Safety and effectiveness are established for the indications described in product labeling.